Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics

References

• Kontoyiannis DP, Marr KA, Park BJ, . Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091–1100.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, . Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010;95:644–650.
   PubMed Web of Science ®Google Scholar
• Gerson SL, Talbot GH, Hurwitz S, . Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100:345–351.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Pautas C, Maury S, . Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042–1051.
   PubMed Web of Science ®Google Scholar
• Ruping MJ, Vehreschild JJ, Cornely OA. Antifungal treatment strategies in high risk patients. Mycoses 2008;51(Suppl. 2):46–51.
   PubMed Web of Science ®Google Scholar
• Mikolajewska A, Schwartz S, Ruhnke M. Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy. Mycoses 2012;55:2–16.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56–e93.
   PubMed Web of Science ®Google Scholar
• Pizzo PA, Robichaud KJ, Gill FA, . Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101–111.
   PubMed Web of Science ®Google Scholar
• Maertens J, Marchetti O, Herbrecht R, . European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant 2011;46:709–718.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, . Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391–1402.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rotstein CM, Betts RF, . Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883–893.
   PubMed Web of Science ®Google Scholar
• Denning DW, Marr KA, Lau WM, . Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006;53:337–349.
   PubMed Web of Science ®Google Scholar
• Toubai T, Tanaka J, Ota S, . Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies. Intern Med 2007;46:3–9.
   PubMed Web of Science ®Google Scholar
• Tamura K, Urabe A, Yoshida M, . Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. Leuk Lymphoma 2009;50:92–100.
   PubMed Web of Science ®Google Scholar
• Kubiak DW, Bryar JM, McDonnell AM, . Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther 2010;32:637–648.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kurokawa T, Ishiyama K, . Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study. Ann Hematol 2011;90:1209–1217.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Tamura K, Imamura M, . Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders. Ann Hematol 2012;91:449–457.
   PubMed Web of Science ®Google Scholar
• Goto N, Hara T, Tsurumi H, . Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies. Am J Hematol 2010;85:872–876.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, . Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C on sensus Group. Clin Infect Dis 2008;46:1813–1821.
   PubMed Web of Science ®Google Scholar
• de Pauw BE, Rubin RH. Empiric versus preemptive therapy in the management of febrile neutropenia in the patient being treated for hematologic malignancy. Transpl Infect Dis 2006;8:1–2.
   PubMed Web of Science ®Google Scholar
• Bennett JE, Powers J, Walsh T, . Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2003;36:S117–S122.
   PubMed Web of Science ®Google Scholar
• Park SY, Lee SO, Choi SH, . Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Infect 2010;61:492–498.
   PubMed Web of Science ®Google Scholar
• de Pauw BE, Sable CA, Walsh TJ, . Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study. Transpl Infect Dis 2006;8:31–37.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348–359.
   Google Scholar
• Viscoli C, Herbrecht R, Akan H, . An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009;64:1274–1281.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Viscoli C. Current role of echinocandins in the management of invasive aspergillosis. Curr Infect Dis Rep 2011;13:517–527.
   PubMedGoogle Scholar
• Wang JL, Chang CH, Young-Xu Y, . Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother 2010;54:2409–2419.
   PubMed Web of Science ®Google Scholar